<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837328</url>
  </required_header>
  <id_info>
    <org_study_id>1605M87323</org_study_id>
    <nct_id>NCT02837328</nct_id>
  </id_info>
  <brief_title>Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias</brief_title>
  <official_title>Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this research is to determine whether oral magnesium supplementation
      in healthy, community-living individuals will be associated with reductions in the burden of
      arrhythmias in the upper chambers of the heart (supraventricular arrhythmias).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the primary objective, the Investigator will conduct a double-blind randomized
      trial assigning participants to receive 400 mg of oral magnesium in the form of magnesium
      citrate once daily or placebo. The investigators will recruit 60 individuals 55 years of age
      and older without a prior history of cardiovascular disease. At baseline, participants will
      undergo a basic examination, answer questionnaires and provide a blood sample to determine
      circulating magnesium levels. Participants will then wear an FDA-approved heart rhythm
      monitor (Zio Â® XT Patch) for 2 weeks. At the end of 2 weeks they will begin taking their
      assigned treatment (magnesium or placebo), and will continue doing so for a total of 12 weeks
      (through study week 14). After 10 weeks of taking the supplement or placebo (study week 12),
      they will have a final study visit in which the participants will provide another blood
      sample for assessment of circulating magnesium, and will be asked to wear the heart rhythm
      monitor for another 2 weeks (through study week 14). The primary endpoint will be the change
      in burden of premature atrial contractions (PACs), measured in episodes per day, between
      baseline and final follow-up visit. A secondary outcome will be the change in circulating
      magnesium between both exams.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">September 15, 2017</completion_date>
  <primary_completion_date type="Actual">September 15, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Premature Atrial Contractions (PACs)</measure>
    <time_frame>Change from Baseline at 10 weeks</time_frame>
    <description>The primary endpoint will be the change in burden of PACs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Magnesium Concentration</measure>
    <time_frame>Baseline and week 10</time_frame>
    <description>The secondary endpoint will be the change in circulating magnesium between baseline and a follow-up visit 10 weeks later.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Premature Atrial Contraction</condition>
  <arm_group>
    <arm_group_label>Oral Magnesium Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg Magnesium Citrate 1x daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Magnesium Supplement</intervention_name>
    <description>400 mg Magnesium Citrate 1x daily for 12 weeks</description>
    <arm_group_label>Oral Magnesium Supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 55 and older

          -  Ability to speak English

          -  Availability to attend baseline and follow-up visit approximately 12 weeks after
             baseline

        Exclusion Criteria:

          -  Prior history of heart disease (coronary heart disease, heart failure, atrial
             fibrillation), stroke, severe renal disease

          -  Use of type I and III antiarrhythmics or digoxin

          -  Current use of magnesium supplements

          -  Any prior history of allergy or intolerance to magnesium

          -  Prior history of inflammatory bowel disease or any severe gastrointestinal disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela L Lutsey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alvaro Alonso, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lin Y Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota - Twin Cities</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>July 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <results_first_submitted>February 1, 2019</results_first_submitted>
  <results_first_submitted_qc>April 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2019</results_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Magnesium Supplementation</keyword>
  <keyword>Magnesium</keyword>
  <keyword>Dietary Supplement</keyword>
  <keyword>Arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Atrial Premature Complexes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02837328/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02837328/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants of 55 years of age or older were recruited using fliers, the University of Minnesota StudyFinder website, invitations to individuals enrolled in the ResearchMatch research volunteer database, and invitations to University of Minnesota School of Public Health employees.</recruitment_details>
      <pre_assignment_details>Participants attended a baseline visit where measurements were conducted and a Zio XT Patch heart rhythm monitor was applied by trained staff. After wearing the patch for 2 weeks, the participants were randomized 1:1 to either magnesium oxide or a placebo using block randomization within two strata of age (younger than 65 and 65 and older).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Magnesium Supplement</title>
          <description>400 mg Magnesium Citrate 1x daily for 12 weeks
Oral Magnesium Supplement: 400 mg Magnesium Citrate 1x daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
Placebo: Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Magnesium Supplement</title>
          <description>400 mg Magnesium Citrate 1x daily for 12 weeks
Oral Magnesium Supplement: 400 mg Magnesium Citrate 1x daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
Placebo: Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="5.3"/>
                    <measurement group_id="B2" value="61.6" spread="5.2"/>
                    <measurement group_id="B3" value="61.5" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Magnesium Concentrations</title>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.74" spread="0.12"/>
                    <measurement group_id="B2" value="1.71" spread=".1"/>
                    <measurement group_id="B3" value="1.72" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Premature Arterial Contractions Burden</title>
          <units>episode/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" spread="14"/>
                    <measurement group_id="B2" value="20.2" spread="80"/>
                    <measurement group_id="B3" value="14.5" spread="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Log Premature Arterial Contractions Burden</title>
          <units>log(Episodes/hour)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.26" spread="1.35"/>
                    <measurement group_id="B2" value="1.04" spread="1.49"/>
                    <measurement group_id="B3" value="1.15" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Premature Atrial Contractions (PACs)</title>
        <description>The primary endpoint will be the change in burden of PACs</description>
        <time_frame>Change from Baseline at 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Magnesium Supplement</title>
            <description>400 mg Magnesium Citrate 1x daily for 12 weeks
Oral Magnesium Supplement: 400 mg Magnesium Citrate 1x daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
Placebo: Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Premature Atrial Contractions (PACs)</title>
          <description>The primary endpoint will be the change in burden of PACs</description>
          <units>Episodes/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="7"/>
                    <measurement group_id="O2" value="-5.6" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Magnesium Concentration</title>
        <description>The secondary endpoint will be the change in circulating magnesium between baseline and a follow-up visit 10 weeks later.</description>
        <time_frame>Baseline and week 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Magnesium Supplement</title>
            <description>400 mg Magnesium Citrate 1x daily for 12 weeks
Oral Magnesium Supplement: 400 mg Magnesium Citrate 1x daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
Placebo: Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Magnesium Concentration</title>
          <description>The secondary endpoint will be the change in circulating magnesium between baseline and a follow-up visit 10 weeks later.</description>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.09"/>
                    <measurement group_id="O2" value="0" spread=".1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>59 days, from day 21 of the intervention to day 80</time_frame>
      <desc>Participants were asked an open-ended question about the occurrence of adverse events. Adverse event information was collected in such a way that individual adverse event terms cannot be separated.</desc>
      <group_list>
        <group group_id="E1">
          <title>Oral Magnesium Supplement</title>
          <description>400 mg Magnesium Citrate 1x daily for 12 weeks
Oral Magnesium Supplement: 400 mg Magnesium Citrate 1x daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
Placebo: Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pamela Lutsey, PhD MPH</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-624-5812</phone>
      <email>lutsey@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

